Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer

OBJECTIVES: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient’s well-being during treatment with nab-paclitaxel plus gemcitabine vs gemcitabine alone as first-line therapy for metastatic pancreatic cancer (MPC) in the Phase III MPACT trial. PARTICIPANTS...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Manag Res
Main Authors: Chiorean, E Gabriela, Von Hoff, Daniel, Wan, Yin, Margunato-Debay, Sandra, Botteman, Marc, Goldstein, David
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2018
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5987855/
https://ncbi.nlm.nih.gov/pubmed/29910636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S163475
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares